JP2008535790A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535790A5 JP2008535790A5 JP2007558290A JP2007558290A JP2008535790A5 JP 2008535790 A5 JP2008535790 A5 JP 2008535790A5 JP 2007558290 A JP2007558290 A JP 2007558290A JP 2007558290 A JP2007558290 A JP 2007558290A JP 2008535790 A5 JP2008535790 A5 JP 2008535790A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- disease
- subject
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 60
- 150000001875 compounds Chemical class 0.000 claims 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 23
- 229940002612 prodrug Drugs 0.000 claims 20
- 239000000651 prodrug Substances 0.000 claims 20
- -1 oxazolopyridyl Chemical group 0.000 claims 18
- 201000010099 disease Diseases 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 10
- 210000003205 muscle Anatomy 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 206010022489 Insulin Resistance Diseases 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000004584 weight gain Effects 0.000 claims 4
- 235000019786 weight gain Nutrition 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 230000001965 increasing effect Effects 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 208000015294 blood coagulation disease Diseases 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 229940044683 chemotherapy drug Drugs 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 230000002438 mitochondrial effect Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 125000002560 nitrile group Chemical group 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 125000003367 polycyclic group Chemical group 0.000 claims 2
- 108010040003 polyglutamine Proteins 0.000 claims 2
- 229920000155 polyglutamine Polymers 0.000 claims 2
- 210000000229 preadipocyte Anatomy 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 230000035882 stress Effects 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 206010000234 Abortion spontaneous Diseases 0.000 claims 1
- 206010056867 Activated protein C resistance Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 201000005657 Antithrombin III deficiency Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 230000005778 DNA damage Effects 0.000 claims 1
- 231100000277 DNA damage Toxicity 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 206010020365 Homocystinuria Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 1
- 201000005660 Protein C Deficiency Diseases 0.000 claims 1
- 206010051292 Protein S Deficiency Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 206010038563 Reocclusion Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 208000001435 Thromboembolism Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims 1
- 230000037147 athletic performance Effects 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 230000032677 cell aging Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 230000020764 fibrinolysis Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 208000033666 hereditary antithrombin deficiency Diseases 0.000 claims 1
- 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 208000015994 miscarriage Diseases 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 235000021049 nutrient content Nutrition 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 230000008723 osmotic stress Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000002510 pyrogen Substances 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000009758 senescence Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 208000000995 spontaneous abortion Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 208000029257 vision disease Diseases 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- CTXHOLCMGDAANM-UHFFFAOYSA-N Cc1nc2ncccc2[o]1 Chemical compound Cc1nc2ncccc2[o]1 CTXHOLCMGDAANM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65851605P | 2005-03-03 | 2005-03-03 | |
| US70561205P | 2005-08-04 | 2005-08-04 | |
| US74178305P | 2005-12-02 | 2005-12-02 | |
| PCT/US2006/007745 WO2006094236A1 (en) | 2005-03-03 | 2006-03-03 | N-phenyl benzamide derivatives as sirtuin modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535790A JP2008535790A (ja) | 2008-09-04 |
| JP2008535790A5 true JP2008535790A5 (enExample) | 2009-04-16 |
Family
ID=36499236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007558290A Pending JP2008535790A (ja) | 2005-03-03 | 2006-03-03 | サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090163476A1 (enExample) |
| EP (1) | EP1853610A1 (enExample) |
| JP (1) | JP2008535790A (enExample) |
| AU (1) | AU2006218404A1 (enExample) |
| CA (1) | CA2599989A1 (enExample) |
| WO (1) | WO2006094236A1 (enExample) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| AU2004312072B2 (en) | 2003-12-29 | 2011-06-23 | President And Fellows Of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US20090142335A1 (en) * | 2005-02-15 | 2009-06-04 | Joslin Diabetes Center | Methods of diagnosis and treatment of metabolic disorders |
| WO2006104586A2 (en) * | 2005-02-15 | 2006-10-05 | Joslin Diabetes Center | Methods of diagnosis and treatment of metabolic disorders |
| WO2006094239A2 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fluorescence polarization assays for acetyltransferase/deacetylase activity |
| ES2397275T3 (es) | 2005-08-04 | 2013-03-05 | Sirtris Pharmaceuticals, Inc. | Derivados de imidazopiridina como agentes moduladores de la sirtuína |
| US7855289B2 (en) * | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US20070077310A1 (en) * | 2005-10-03 | 2007-04-05 | University Of Tennessee Research Foundation | Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species |
| ES2389111T3 (es) * | 2005-12-02 | 2012-10-23 | Sirtris Pharmaceuticals, Inc. | Ensayos de espectrometría de masas para la actividad acetiltransferasa/desacetilasa |
| AU2007213451B2 (en) | 2006-02-10 | 2013-02-07 | Summit (Oxford) Limited | Treatment of Duchenne muscular dystrophy |
| WO2008024435A2 (en) * | 2006-08-23 | 2008-02-28 | Vanderbilt University | Dendritic molecular intracellular transporters and methods of making and using same |
| WO2008029152A2 (en) * | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| CN101616667A (zh) | 2006-10-27 | 2009-12-30 | 百时美施贵宝公司 | 可用作激酶抑制剂的杂环酰胺化合物 |
| CL2008001822A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| TW200918542A (en) | 2007-06-20 | 2009-05-01 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| CL2008002279A1 (es) | 2007-08-03 | 2009-11-27 | Summit Corp Plc | Combinacion farmaceutica que comprende un compuesto heteroarilbiciclico o arilbiciclico y un agente auxiliar; proceso de preparacion; y envase farmaceutico, util en el tratamiento y/o profilaxis de la distrofia muscular de duchenne, distrofia muscular de becker y caquexia. |
| US20090239868A1 (en) * | 2007-10-23 | 2009-09-24 | Institute Of Medical Molecular Design, Inc. | Inhibitor of pai-1 production |
| JP2011500810A (ja) * | 2007-10-23 | 2011-01-06 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 運動を模倣するためのｓｉｒｔ−３関連方法及び組成物 |
| WO2009058348A1 (en) * | 2007-11-01 | 2009-05-07 | Sirtris Pharmaceuticals, Inc. | Amide derivatives as sirtuin modulators |
| US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| US20110274620A1 (en) * | 2007-11-05 | 2011-11-10 | Harth Eva M | Multifunctional degradable nanoparticles with control over size and functionalities |
| WO2009061854A2 (en) | 2007-11-05 | 2009-05-14 | Vanderbilt University | Multifunctional degradable nanoparticles with control over size and functionalities |
| US20130142733A1 (en) | 2007-11-05 | 2013-06-06 | Vanderbilt University | Multifunctional degradable nanoparticles with control over size and functionalities |
| US11254786B2 (en) | 2007-11-05 | 2022-02-22 | Vanderbilt University | Multifunctional degradable nanoparticles with control over size and functionalities |
| CN101910184A (zh) * | 2007-11-08 | 2010-12-08 | 西特里斯药业公司 | 可溶性噻唑并吡啶 |
| US8067409B2 (en) | 2007-11-27 | 2011-11-29 | Abbott Laboratories | Protein kinase inhibitors |
| RU2364597C1 (ru) * | 2007-12-14 | 2009-08-20 | Андрей Александрович Иващенко | ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ |
| EA021938B1 (ru) * | 2008-05-01 | 2015-10-30 | Сертрис Фармасьютикалз, Инк. | Хинолины и их аналоги в качестве модуляторов сиртуина |
| CN104193740A (zh) | 2008-07-03 | 2014-12-10 | 西特里斯药业公司 | 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物 |
| RU2519779C2 (ru) | 2008-09-29 | 2014-06-20 | Сертрис Фармасьютикалз Инк. | Хиназолинон, хинолон и родственные аналоги в качестве модуляторов сиртуина |
| EP2179984A1 (en) * | 2008-10-27 | 2010-04-28 | Congenia S.r.l. | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition |
| AU2009333588A1 (en) | 2008-12-08 | 2011-07-21 | Northwestern University | Method of modulating HSF-1 |
| CN102388054B (zh) * | 2008-12-19 | 2015-03-04 | 西特里斯药业公司 | 噻唑并吡啶沉默调节蛋白调节剂的化合物 |
| CN102573473B (zh) | 2009-06-09 | 2015-05-27 | 加利福尼亚资本权益有限责任公司 | 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物 |
| CN102573480B (zh) | 2009-06-09 | 2015-06-10 | 加利福尼亚资本权益有限责任公司 | 三嗪衍生物及其治疗应用 |
| CA2765044A1 (en) | 2009-06-09 | 2010-12-16 | California Capital Equity, Llc | Benzyl substituted triazine derivatives and their therapeutical applications |
| EP2445868B1 (en) * | 2009-06-22 | 2013-12-18 | F.Hoffmann-La Roche Ag | Biphenyl amides useful as p2x3 and/or p2x2/3 receptors modulators |
| JP2013509442A (ja) | 2009-10-29 | 2013-03-14 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュイン調節因子としての二環式ピリジンおよび類似体 |
| US9603862B2 (en) * | 2009-12-14 | 2017-03-28 | Cornell University | Activation and activators of SIRT5 |
| EP2332528A1 (de) * | 2009-12-14 | 2011-06-15 | Grünenthal GmbH | Substituierte aromatische Dicarbonsäureamide als Arzneimittel |
| WO2011111070A2 (en) * | 2010-03-09 | 2011-09-15 | Bdr Pharmaceuticals International Pvt. Ltd. | Novel injectable combination |
| WO2011118812A1 (ja) * | 2010-03-26 | 2011-09-29 | 国立大学法人北海道大学 | 神経変性疾患治療薬 |
| JP6038773B2 (ja) * | 2010-04-15 | 2016-12-07 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュイン活性化因子および活性化アッセイ |
| CN107988228B (zh) | 2010-05-03 | 2022-01-25 | 库尔纳公司 | 通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病 |
| EP2388255A1 (en) * | 2010-05-11 | 2011-11-23 | Ikerchem, S.L. | Polysubstituted benzofurans and medicinal applications thereof |
| BR112013006016A2 (pt) * | 2010-09-15 | 2016-06-07 | Hoffmann La Roche | compostos de azabenzotiazol, composições e métodos de uso |
| EP2635554A2 (en) * | 2010-11-01 | 2013-09-11 | Neurotune AG | Novel neurotrypsin inhibitors |
| US20130261130A1 (en) * | 2010-11-01 | 2013-10-03 | Shaheen Ahmed | Neurotrypsin inhibitors |
| RU2631597C2 (ru) | 2011-07-15 | 2017-09-25 | Нусерт Сайенсиз, Инк. | Композиции и способы модулирования метаболических путей |
| WO2013022793A1 (en) * | 2011-08-05 | 2013-02-14 | The Regents Of The University Of California | Small molecule activators of calcium-activated chloride channels and methods of use |
| WO2013074948A1 (en) | 2011-11-16 | 2013-05-23 | Resveratrol Partners, Llc | Compositions containing resveratrol and nucleotides |
| US20150010474A1 (en) * | 2011-12-23 | 2015-01-08 | Auckland Uniservices Limited | Compounds And Methods For Selective Imaging And/Or Ablation |
| CN102633668B (zh) * | 2012-01-20 | 2015-05-06 | 天舒生物技术有限公司 | 化合物在转录因子失调相关疾病的治疗药物中的应用 |
| US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
| US20150133527A1 (en) * | 2012-05-04 | 2015-05-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Regulation of cardiac sodium channels by sirt1 and sirt1 activators |
| CN108452311A (zh) | 2012-11-13 | 2018-08-28 | 纽斯尔特科学公司 | 用于增强能量代谢的组合物和方法 |
| EP2968333B1 (en) | 2013-03-15 | 2022-01-12 | NuSirt Sciences, Inc. | Leucine and nicotinic acid for the reduction of lipid levels |
| SG11201607075TA (en) | 2014-02-27 | 2016-09-29 | Nusirt Sciences Inc | Compositions and methods for the reduction or prevention of hepatic steatosis |
| WO2015143654A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| JPWO2016148114A1 (ja) * | 2015-03-13 | 2018-01-18 | 国立大学法人北海道大学 | 酸化ストレス誘導神経細胞死抑制化合物 |
| CN106191215B (zh) | 2015-04-29 | 2020-03-24 | 中国科学院上海生命科学研究院 | 肌肉萎缩相关的蛋白质分子标记Dkk-3的筛选及其应用 |
| BR112018011639A2 (pt) * | 2015-12-08 | 2018-11-27 | Biomatrica Inc | redução de taxa de sedimentação de eritrócitos |
| US20220168337A1 (en) * | 2016-03-30 | 2022-06-02 | Hemotek, Llc | Producing atp and improving mitochondrial function in a mammal using a poly-oxygenated metal hydroxide |
| CN106117078A (zh) * | 2016-06-28 | 2016-11-16 | 东南大学 | 5‑硝基‑4‑羟基间苯二酰胺类化合物在制备抗肿瘤药物中的应用 |
| AU2017335902B2 (en) | 2016-09-28 | 2023-08-24 | Abraxis Bioscience, Llc | Methods of treating mitochondrial and metabolic disorders |
| WO2019099426A1 (en) * | 2017-11-17 | 2019-05-23 | Icahn School Of Medicine At Mount Sinai | Influenza virus inhibitor targeting nucleoprotein |
| CN108864038A (zh) * | 2018-06-12 | 2018-11-23 | 浙江大学 | 3-酰胺基-n-芳基苯甲酰胺类化合物及制备和应用 |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| WO2021067393A1 (en) * | 2019-10-01 | 2021-04-08 | Memorial Sloan Kettering Cancer Center | SMALL MOLECULE INHIBITORS OF Id PROTEINS |
| MX2022006397A (es) * | 2019-12-02 | 2022-06-24 | Academia Sinica | Inhibidores de pdia4 y su uso para inhibir la patogenesis de celulas ? y para tratar diabetes. |
| US20230086683A1 (en) * | 2020-01-15 | 2023-03-23 | Platefuse, Inc. | Platelet storage methods and compositions |
| WO2021240187A1 (en) | 2020-05-29 | 2021-12-02 | Semmelweis Egyetem | Benzamide derivatives as anti-inflammatory compounds and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3164603A (en) * | 1965-01-05 | xnhcox | ||
| US3503929A (en) * | 1965-10-21 | 1970-03-31 | Minnesota Mining & Mfg | Polyimidazoquinazolines and polyamidobenzimidazoles |
| US3517007A (en) * | 1968-04-05 | 1970-06-23 | American Home Prod | 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds |
| US3712888A (en) * | 1970-12-14 | 1973-01-23 | American Cyanamid Co | Bis-pyridoxazole-stilbene derivatives for optical brightening |
| US3828228A (en) * | 1973-03-05 | 1974-08-06 | Hewlett Packard Co | Microwave transistor package |
| US4038396A (en) * | 1975-02-24 | 1977-07-26 | Merck & Co., Inc. | Anti-inflammatory oxazole[4,5-b]pyridines |
| US4018932A (en) * | 1975-11-03 | 1977-04-19 | American Cyanamid Company | Anthelmintic pour-on formulations for topical use on domestic and farm animals |
| JPS6040016B2 (ja) * | 1977-08-31 | 1985-09-09 | コニカ株式会社 | マゼンタ色素画像の形成方法 |
| US4471040A (en) * | 1980-09-10 | 1984-09-11 | Canon Kabushiki Kaisha | Electrophotographic disazo photosensitive member |
| US4939133A (en) * | 1985-10-01 | 1990-07-03 | Warner-Lambert Company | N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade |
| US5814651A (en) * | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
| ES2172585T3 (es) * | 1994-05-31 | 2002-10-01 | Mitsui Chemicals Inc | Derivado de benzoimidazol. |
| WO1997012613A1 (en) * | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US5808087A (en) * | 1995-11-29 | 1998-09-15 | Mitsui Chemicals, Inc. | Sulfonium salts of pyrrolylbenzimidazoles |
| US6653309B1 (en) * | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
| CA2373510A1 (en) * | 1999-05-12 | 2000-11-23 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
| US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| US20040010033A1 (en) * | 2001-02-20 | 2004-01-15 | Pfizer Inc. | Non-peptide GnRH agents, methods and intermediates for their preparation |
| US7081454B2 (en) * | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| CA2450555A1 (en) * | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| WO2003007959A1 (en) * | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| US8354397B2 (en) * | 2001-07-27 | 2013-01-15 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| WO2004043335A2 (en) * | 2001-09-13 | 2004-05-27 | Genesoft, Inc. | Methods of treating infection by drug resistant bacteria |
| US7163952B2 (en) * | 2001-12-03 | 2007-01-16 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
| MXPA04007697A (es) * | 2002-02-06 | 2004-11-10 | Vertex Pharma | Compuestos de heteroarilo utiles como inhibidores de gsk-3. |
| ATE432261T1 (de) * | 2002-03-18 | 2009-06-15 | Merck Frosst Canada Ltd | Pde4-inhibitoren mit heterobrückensubstituiertem 8-arylchinolin |
| TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| NZ535764A (en) * | 2002-04-18 | 2007-10-26 | Schering Corp | 1-(4-piperidinyl) benzimidazolones as histamine H3 antagonists |
| CN1304371C (zh) * | 2002-07-12 | 2007-03-14 | 塞诺菲-安万特德国有限公司 | 杂环取代的苯甲酰脲、其药物和制备药物的用途 |
| TW200501960A (en) * | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| WO2004032716A2 (en) * | 2002-10-08 | 2004-04-22 | Massachusetts Institute Of Technology | Compounds for modulation of cholesterol transport |
| EP1551809A1 (en) * | 2002-10-09 | 2005-07-13 | Pfizer Products Inc. | Pyrazole compounds for treatment of neurodegenerative disorders |
| WO2004041277A1 (en) * | 2002-11-01 | 2004-05-21 | Merck & Co., Inc. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
| WO2004046122A2 (en) * | 2002-11-16 | 2004-06-03 | Oxford Glycosciences (Uk) Ltd | Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors |
| AU2003302497A1 (en) * | 2002-11-27 | 2004-06-23 | Ph. D. Edward M. Eddy | Glyceraldehyde 3-phosphate dehydrogenase-s(gapds), a glycolytic enzyme expressed only in male germ cells,is a target for male contraception |
| JP2006517234A (ja) * | 2003-02-10 | 2006-07-20 | アムジエン・インコーポレーテツド | バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用 |
| US7157460B2 (en) * | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| AU2004215428B2 (en) * | 2003-02-26 | 2009-08-27 | Sugen LLC | Aminoheteroaryl compounds as protein kinase inhibitors |
| DE602004015429D1 (de) * | 2003-03-11 | 2008-09-11 | Pfizer Prod Inc | Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf) |
| US20040245539A1 (en) * | 2003-06-06 | 2004-12-09 | Tien-Yu Chen | Light-emitting diode light string |
| JP2007505851A (ja) * | 2003-09-19 | 2007-03-15 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシン受容体リガンドとしてのチアゾピリジン誘導体 |
| US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| ES2397275T3 (es) * | 2005-08-04 | 2013-03-05 | Sirtris Pharmaceuticals, Inc. | Derivados de imidazopiridina como agentes moduladores de la sirtuína |
| KR20070035266A (ko) * | 2005-09-27 | 2007-03-30 | 삼성전자주식회사 | 소프트웨어 검사방법 |
| TW200918542A (en) * | 2007-06-20 | 2009-05-01 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| US20100168084A1 (en) * | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
-
2006
- 2006-03-03 EP EP06736981A patent/EP1853610A1/en not_active Withdrawn
- 2006-03-03 US US11/885,577 patent/US20090163476A1/en not_active Abandoned
- 2006-03-03 WO PCT/US2006/007745 patent/WO2006094236A1/en not_active Ceased
- 2006-03-03 AU AU2006218404A patent/AU2006218404A1/en not_active Abandoned
- 2006-03-03 JP JP2007558290A patent/JP2008535790A/ja active Pending
- 2006-03-03 CA CA002599989A patent/CA2599989A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535790A5 (enExample) | ||
| RU2315757C9 (ru) | Замещенные 2-тио-3,5-дициано-4-фенил-6-аминопиридины и лекарственное средство на их основе | |
| US20240208967A1 (en) | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | |
| AU2015226855B2 (en) | Human plasma kallikrein inhibitors | |
| JP6407955B2 (ja) | クマリン誘導体、ならびに過剰増殖疾患を治療する際の使用方法 | |
| US9695160B2 (en) | Piperazine derivatives for treating disorders | |
| RU2594282C2 (ru) | Средства, вызывающие апоптоз, для лечения злокачественных новообразований и иммунных и аутоиммунных заболеваний | |
| JP6713928B2 (ja) | Ｕｒａｔ１阻害剤 | |
| KR20180134908A (ko) | 항-세포자멸적 bcl-2 계열 단백질의 열화를 유도하는 화합물 및 이의 용도 | |
| JP2016505063A (ja) | ソルチリン阻害剤としてのｎ置換された５置換フタルアミド酸 | |
| CN103958508A (zh) | 用于治疗癌症以及免疫与自身免疫性疾病的细胞凋亡诱导剂 | |
| KR101866706B1 (ko) | 1-알킬-6-옥소-1,6-디하이드로피리딘-3-일 화합물과 sgrm 조절인자로서의 용도 | |
| JP2021523887A (ja) | ＸＩＩａ因子インヒビター | |
| MX2012006349A (es) | Derivados de n-aciloxisulfonamida y n-hidroxi-n-acilsulfonamida. | |
| US10696661B2 (en) | Compounds | |
| KR102738491B1 (ko) | 오렉신 수용체 조정제로서의 할로-치환된 피페리딘 | |
| RU2007116850A (ru) | Антагонисты рецептора тромбина | |
| US20240398776A1 (en) | Inhibitors of tgf-beta r1 (alk5) useful to treat cell proliferation disorders | |
| US20090018145A1 (en) | Compositions and their use as anti-tumor agents | |
| JP2016514714A (ja) | 尿素誘導体及びその脂肪酸結合タンパク質（ｆａｂｐ）阻害剤としての使用 | |
| JP2024510132A (ja) | Ｆｐｒ１のモジュレーター及びそれを使用する方法 | |
| TW201522288A (zh) | α－取代甘胺醯胺衍生物 | |
| KR20160006717A (ko) | S100-저해제로서 유용한 n-(헤테로아릴)-설폰아미드 유도체 | |
| AU2019256672B2 (en) | Substituted propanamides as inhibitors of nucleases | |
| CN110078735B (zh) | 具有抗肿瘤活性的吡咯并嘧啶化合物及其用途 |